Research programme: nitric oxide scavengers - AnorMED

Drug Profile

Research programme: nitric oxide scavengers - AnorMED

Latest Information Update: 04 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnorMED
  • Developer The Institute of Cancer Research; University of Alberta; University of Calgary
  • Class
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Septic shock; Stroke

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 30 Jul 2002 AnorMED is actively seeking partnering/licensing opportunities for its nitric oxide scavengers programme
  • 29 Aug 2001 Preclinical development for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top